Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)

European Heart Journal

Volumn 35, Issue 47, 2014, Pages 3365-3376

  Lip, Gregory Y H ^a   Laroche, Cecile ^b   Ioachim, Popescu Mircea ^c   Rasmussen, Lars Hvilsted ^d   Vitali Serdoz, Laura ^e   Petrescu, Lucian ^f   Darabantiu, Dan ^g   Crijns, Harry J G M ^h   Kirchhof, Paulus ^a   Vardas, Panos ⁱ   Tavazzi, Luigi ^j   Maggioni, Aldo P ^k,l   Boriani, Giuseppe ^m  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b European Society of Cardiology   (France)

^c University of Oradea   (Romania)

^d AALBORG UNIVERSITY   (Denmark)

^e UNIVERSITY OF TRIESTE   (Italy)

^f Institute of Cardiovascular Diseases   (Romania)

^g Emergency County Hospital   (Romania)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^j MARIA CECILIA HOSPITAL   (Italy)

^k ANMCO RESEARCH CENTER   (Italy)

^l EORP Team European Society of Cardiology   (France)

^m UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

Atrial fibrillation; Mortality; Prognosis; Registry; Stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ANTIARRHYTHMIC AGENT; FIBRINOLYTIC AGENT; VITAMIN K GROUP;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOLOGIST; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DYSPNEA; ELECTROCARDIOGRAPHY; EMBOLISM; FATIGUE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART PALPITATION; HEART RHYTHM; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PAROXYSMAL HEART ATRIUM FIBRILLATION; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; REGISTER; TACHYCARDIA; TRANSIENT ISCHEMIC ATTACK; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; CARDIOLOGY; CLINICAL TRIAL; EPIDEMIOLOGY; EUROPE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIOLOGY; EPIDEMIOLOGIC METHODS; EUROPE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; PROGNOSIS; VITAMIN K;

EID: 84920001478     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu374     Document Type: Article

References (34)

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-1413
2. Sweeney KG, GrayDP, Steele R, Evans P. Use of warfarin in non-rheumatic atrial fibrillation: a commentary from general practice. Br J Gen Pract 1995; 45: 153-158
3. LipGY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?. Eur Heart J 2013; 34: 1041-1049
4. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, DaviesDW, Cobbe S, Breithardt G, Le Heuzey JY, Prins MH, Levy S, Crijns HJ. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-2434
5. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Oliveira MM, Mairesse G, Crijns HJ, Simantirakis E, Atar D, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP. A prospective survey in European Society of Cardiology member countries of atrial fibrillationmanagement: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16: 308-319
6. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Ioachim PM, Tica O, Boriani G, Cimaglia P, Diemberger I, Hellum CF, Mortensen B, Maggioni AP. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey. Am J Med 2014; 127: 519-529.e1
7. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-1420
8. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272
9. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100
10. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, Schmitt J, ZamoranoJL. Management of atrial fibrillation in sevenEuropean countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events-European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014; 16: 6-14
11. Le Heuzey JY, Ammentorp B, Darius H, De Caterina R, Schilling RJ, Schmitt J, Zamorano JL, Kirchhof P. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF Registry. Thromb Haemost 2014; 111: 833-841
12. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Turpie AG, van Eickels M, Misselwitz F, Rushton-Smith S, Kayani G, Wilkinson P, Verheugt FW. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PloS One 2013; 8: e63479
13. Piccini JP, Fraulo ES, Ansell JE, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Kong MH, Lopes RD, Mills RM, Peterson ED. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J 2011; 162: 606-612.e1
14. Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, Gupta D. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace 2014; 16: 965-972
15. Lane DA, Lip GY. Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost 2014; 111: 381-383
16. National-Institute-for-Health-And-Care-Excellence. Atrial fibrillation: the management of atrial fibrillation 2014 (Clinical guideline 180) http://guidance.nice.org. uk/CG180
17. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J 1990; 63: 225-227
18. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH, Lopez-Sendon J, Vardas PE, Aliot E, Santini M, Crijns HJ. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27: 3018-3026
19. Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, Bradley SM, Maddox TM, Grunwald GK, Baron AE, Rumsfeld JS, Varosy PD, Schneider PM, Marzec LN, Ho PM. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the Veterans Health Administration. Am Heart J 2014; 167: 810-817
20. Thorne K, Jayathissa S, Dee S, Briggs N, Taylor J, Reid S, DeSilva K, Dean J. Adherence and outcomesof patients prescribed dabigatran (Pradaxa) in routine clinical practice. Intern Med J 2014; 44: 261-265
21. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367: 625-635
22. Lau YC, Lane DA, Lip GY. Atrial fibrillation and heart failure: a bad combination. Am J Cardiol 2014; 113: 1196-1197
23. Girerd N, Pibarot P, Daleau P, Voisine P, O'Hara G, Despres JP, Mathieu P. Statins reduce short- And long-Term mortality associated with postoperative atrial fibrillation after coronary artery bypass grafting: impact of postoperative atrial fibrillation and statin therapy on survival. Clin Cardiol 2012; 35: 430-436
24. Naci H, Brugts JJ, Fleurence R, Tsoi B, Toor H, Ades AE. Comparative benefits of statins in the primary and secondary prevention of major coronary events and allcause mortality: a network meta-Analysis of placebo-controlled and activecomparator trials. Eur J Prev Cardiol 2013; 20: 641-657
25. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003; 14: 666-672
26. Friberg L, Rosenqvist M. Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: report from the Stockholm Cohort Study of Atrial Fibrillation. Europace 2011; 13: 626-633
27. Mitchell LB, Southern DA, Galbraith D, GhaliWA, Knudtson M, Wilton SB. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart 2014; doi: 10.1136/heartjnl-2013-305303
28. Paoletti Perini A, Bartolini S, Pieragnoli P, Ricciardi G, Perrotta L, Valleggi A, Vergaro G, Michelotti F, Boggian G, Sassone B, Mascioli G, Emdin M, Padeletti L. CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy. Europace 2014; 16: 71-80
29. Svendsen JH, Nielsen JC, Darkner S, Jensen GV, Mortensen LS, Andersen HR. CHADS2 and CHA2DS2-VASc score to assess risk of stroke and death in patients paced for sick sinus syndrome. Heart 2013; 99: 843-848
30. Ntaios G, Lip GY, Makaritsis K, Papavasileiou V, Vemmou A, Koroboki E, Savvari P, Manios E, Milionis H, Vemmos K. CHADS(2), CHA(2)S(2)DS(2)-VASc, and longterm stroke outcome in patients without atrial fibrillation. Neurology 2013; 80: 1009-1017
31. Taillandier S, Olesen JB, Clementy N, Lagrenade I, Babuty D, Lip GY, Fauchier L. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score ' 0 in a community-based cohort study. J Cardiovasc Electrophysiol 2012; 23: 708-713
32. Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, Zhu J, Jansky P, Sigamani A, Morillo CA, Liu L, Damasceno A, Grinvalds A, Nakamya J, Reilly PA, Keltai K, Van Gelder IC, Yusufali AH, Watanabe E, Wallentin L, Connolly SJ, Yusuf S. Variations in cause and management of atrial fibrillation in a prospective registry of 15, 400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 2014; 129: 1568-1576
33. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107
34. Gallego P, Roldan V, Marin F, Romera M, Valdes M, Vicente V, Lip GY. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198